I live in the Southern Tier of NY, right next to the “Norther Tier of Pennsylvania.
Although I live in NY, MY hospital is in Pennsylvania. My clinic (a fully staffed medical facility) is here in NY where I go to the doctor. They are directly affiliated with the major hospital in Pennsylvania. It is the CLOSEST MAJOR hospital in my area. Our local hospital is a community hospital.
Were myself or my wife to get COVID-19 we would travel the 38.8 miles to be treated in Pennsylvania, as we already do for anything important.
New York
“ No pharmacist shall dispense hydroxychloroquine or chloroquine except when written as prescribed for an FDA-approved indication; or as part of a state approved clinical trial related to COVID-19 for a patient who has tested positive for COVID-19, with such test result documented as part of the prescription. No other experimental or prophylactic use shall be permitted, and any permitted prescription is limited to one 14-day prescription with no refills.”
Pennsylvania
In response to COVID-19 and potential shortages of medications that may be effective against the virus such as hydroxychloroquine, pharmacists should verify the patient is confirmed COVID-19 positive before dispensing. Patients established on therapy or utilizing the medication for other diagnoses (e.g. Lupus or Rheumatoid Arthritis) should be able to continue to access without diagnosis verification. Smaller quantities of hydroxychloroquine should be dispensed to COVID-19 patients when appropriate to prevent potential shortages.
https://naspa.us/resource/hydroxychloroquine-chloroquine-and-azithromycin/
for ALL states at link.
so for Virginia what does this mean to us?
Prescriptions for chloroquine, hydroxychloroquine, mefloquine and azithromycin should be restricted in the outpatient setting and should require a diagnosis “consistent with the evidence for its use.”
Community pharmacists should use professional judgement to determine whether a prescription is valid and that there is a bona fide practitioner-patient relationship prior to dispensing.
Prioritize treatment for continuation of existing medication therapy, inpatient settings, and other indications where there is not an alternative therapy.